Disease · MONDO_0002746

fallopian tube adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. fallopian tube adenocarcinoma. Diseases, record MONDO_0002746. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002746

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: fallopian tube adenocarcinoma; Open Targets
Open Targets ID: MONDO_0002746; Open Targets
Other names: adenocarcinoma of fallopian tube, adenocarcinoma of the fallopian tube; Open Targets
Disease Ontology: DOID:3706; Disease Ontology
NCI Thesaurus: C6265; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 13 drugs, from ClinicalTrials.gov; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ATRASENTAN	CHEMBL9194	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
HU3S193	CHEMBL2109506		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets34

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 inhibitor	Phase 3	https://conductscience.org/library/genes/29126	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	1	Macrophage colony stimulating factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/1436	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1493	Drugs and targets
EDNRA	Endothelin-1 receptor	1	Endothelin receptor ET-A antagonist	Phase 2	https://conductscience.org/library/genes/1909	Drugs and targets
FGFR1	Fibroblast growth factor receptor 1	1	Fibroblast growth factor receptor 1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2260	Drugs and targets
FGFR3	Fibroblast growth factor receptor 3	1	Fibroblast growth factor receptor 3 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2261	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2324	Drugs and targets
ITK	Tyrosine-protein kinase ITK/TSK	1	Tyrosine-protein kinase ITK/TSK inhibitor	Phase 1/2	https://conductscience.org/library/genes/3702	Drugs and targets

1 to 10 of 34

See all 34 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01137071	Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Phase 2	29	2016-12-29	Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer	HU3S193	Its record names the disease	ClinicalTrials.gov
NCT01035658	Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma	Phase 1/2	22	2015-05-21	Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma	DOXORUBICIN, PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT00653328	Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma	Phase 2	15	2011-04-21	Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer	ATRASENTAN, DOXORUBICIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02891824	ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab	Phase 3	614		Ovarian Cancer	ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02659384	Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer	Phase 2	122		Ovarian Neoplasms	ASPIRIN, ATEZOLIZUMAB, BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03249142	Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer	Phase 1/2	69		Ovarian Cancer	CARBOPLATIN, DURVALUMAB, PACLITAXEL, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT04575961	Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer	Phase 2	33		Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Cancer	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Platinum Refractory Disease vs Platinum Sensitive Disease: Response Rate in the Subsets of Patients With Platinum-sensitive and Platinum-refractory Ovarian Carcinoma	3 of 8	5 of 11	19	NCT01035658

Source Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41108824	DERIVED	1	PubMed
37643382	DERIVED	1	PubMed
37185961	DERIVED	1	PubMed
33664128	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002746

GET https://conductscience.org/api/diseases/v1/MONDO_0002746/targets?page=2

API reference For AI assistants